Xencor, Inc. develops antibody and protein therapeutics to treat cancer and autoimmune inflammation. The Company markets its products to healthcare providers and facilities throughout the United States and internationally.

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

Current Report (Form 8-K | Period ending 2025-11-05)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Xencor Inc (XNCR US)

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

Current Report (Form 8-K | Period ending 2025-11-05)

Current Report (Form 8-K | Period ending 2025-10-24)

Quarterly Report (Form 10-Q | Period ending 2025-06-30)

Current Report (Form 8-K | Period ending 2025-08-06)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)